At Minoryx, we are committed to finding innovative treatments for life threatening rare diseases.


Marc Martinell, PhD
Co-Founder & Chief Executive Officer

Minoryx is a clinical stage biotech company leading the development of new therapies for X-ALD and other Orphan CNS diseases, a group of rare diseases of genetic origin with a high unmet medical need. The company’s leading program, a differentiated PPAR gamma agonist (MIN-102; leriglitazone), is a candidate for X-linked Adrenoleukodystrophy that has successfully completed phase 1 clinical trials, and is now in a pivotal phase 2/3 trial in adult X-linked Adrenoleukodystrophy (X-ALD) patients with Adrenomyeloneuropathy (AMN) and phase 2 trial in Friedreich’s Ataxia (FRDA) . Minoryx harnesses its unique mechanism of action for potential use in X-ALD and FRDA, two genetic diseases characterized by progressive neurological deterioration with no available pharmacological treatment.

Minoryx is also working on expanding the use of MIN-102 into other CNS diseases.

All our activities are performed under an ethical code which is driven by the following values:


One of the biggest assets of the company is our team, a group of professionals fully committed to the task of delivering new treatments for rare diseases.

Social responsibility:

Minoryx and their employees are absolutely dedicated to relieving people’s suffering from rare diseases, especially children and their families.

Innovation & Dynamism:

We innovate by exploiting state of the art technologies. We form synergistic partnerships for drug discovery and provide them with an environment which fosters creativity and open-mindedness.

Added Value:

We strive to provide life-changing treatments for diseases with highly unmet medical needs.